Recruiting
Study to Evaluate Safety, Tolerability and Drug Levels of BMS-986435/MYK-224 in Participants With Heart Failure With Preserved Ejection Fraction (HFpEF) - CV029-1001
Mis à jour:
6 mai, 2026
|
ClinicalTrials.gov
Résumé imprimable
Détails de l’essai
-
Phase 2
Phase
-
Sexe(s)
-
40-85
Tranche d’âge
-
47
Site(s)
-
Recruiting
Options de traitement
Principaux critères d’éligibilité
Key Inclusion Criteria: - Adult participants with stable, symptomatic HFpEF with a normal heart pumping ability Key Exclusion Criteria: - Participants must not have a known diagnosis of obstructive or genetic hypertrophic cardiomyopathy or infiltrative/storage disorder such as cardiac amyloidosis, or any other acute or serious condition that could interfere with assessments during the study or may pose a risk to the participant Note: Other protocol-defined inclusion/exclusion criteria apply